Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2 article

Mauro Piacentini, Andrea Baiocchini, Franca Del Nonno, Gerry Melino, Nickolai A. Barlev, Federica Rossin, Manuela D'Eletto, Laura Falasca

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most important liver diseases worldwide. Currently, no effective treatment is available, and NAFLD pathogenesis is incompletely understood. Transglutaminase type 2 (TG2) is a ubiquitous enzyme whose dysregulation is implicated in the pathogenesis of various human diseases. Here we examined the impact of TG2 on NAFLD progression using the high-fat-diet-induced model in both wild-type and TG2-deficient mice. Animals were fed with a standard chow diet or a high-fat diet (42% of the energy from fat) for 16 weeks. Results demonstrated that the absence of a functional enzyme, which causes the impairment of autophagy/mitophagy, leads to worsening of disease progression. Data were confirmed by pharmacological inhibition of TG2 in WT animals. In addition, the analysis of human liver samples from NAFLD patients validated the enzyme's involvement in the liver fat disease pathogenesis. Our findings strongly suggest that TG2 activation may offer protection in the context of NAFLD, thus representing a novel therapeutic target for tackling the NAFLD progression.

Original languageEnglish
Article number257
JournalCell Death and Disease
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Disease Progression
High Fat Diet
Liver Diseases
Enzymes
Mitochondrial Degradation
Fats
Autophagy
transglutaminase 2
Non-alcoholic Fatty Liver Disease
Pharmacology
Diet
Liver
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2 article. / Piacentini, Mauro; Baiocchini, Andrea; Del Nonno, Franca; Melino, Gerry; Barlev, Nickolai A.; Rossin, Federica; D'Eletto, Manuela; Falasca, Laura.

In: Cell Death and Disease, Vol. 9, No. 3, 257, 01.03.2018.

Research output: Contribution to journalArticle

@article{35431e3151804a4bb5ba3fefa6480a1f,
title = "Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2 article",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is one of the most important liver diseases worldwide. Currently, no effective treatment is available, and NAFLD pathogenesis is incompletely understood. Transglutaminase type 2 (TG2) is a ubiquitous enzyme whose dysregulation is implicated in the pathogenesis of various human diseases. Here we examined the impact of TG2 on NAFLD progression using the high-fat-diet-induced model in both wild-type and TG2-deficient mice. Animals were fed with a standard chow diet or a high-fat diet (42{\%} of the energy from fat) for 16 weeks. Results demonstrated that the absence of a functional enzyme, which causes the impairment of autophagy/mitophagy, leads to worsening of disease progression. Data were confirmed by pharmacological inhibition of TG2 in WT animals. In addition, the analysis of human liver samples from NAFLD patients validated the enzyme's involvement in the liver fat disease pathogenesis. Our findings strongly suggest that TG2 activation may offer protection in the context of NAFLD, thus representing a novel therapeutic target for tackling the NAFLD progression.",
author = "Mauro Piacentini and Andrea Baiocchini and {Del Nonno}, Franca and Gerry Melino and Barlev, {Nickolai A.} and Federica Rossin and Manuela D'Eletto and Laura Falasca",
year = "2018",
month = "3",
day = "1",
doi = "10.1038/s41419-018-0292-8",
language = "English",
volume = "9",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2 article

AU - Piacentini, Mauro

AU - Baiocchini, Andrea

AU - Del Nonno, Franca

AU - Melino, Gerry

AU - Barlev, Nickolai A.

AU - Rossin, Federica

AU - D'Eletto, Manuela

AU - Falasca, Laura

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Non-alcoholic fatty liver disease (NAFLD) is one of the most important liver diseases worldwide. Currently, no effective treatment is available, and NAFLD pathogenesis is incompletely understood. Transglutaminase type 2 (TG2) is a ubiquitous enzyme whose dysregulation is implicated in the pathogenesis of various human diseases. Here we examined the impact of TG2 on NAFLD progression using the high-fat-diet-induced model in both wild-type and TG2-deficient mice. Animals were fed with a standard chow diet or a high-fat diet (42% of the energy from fat) for 16 weeks. Results demonstrated that the absence of a functional enzyme, which causes the impairment of autophagy/mitophagy, leads to worsening of disease progression. Data were confirmed by pharmacological inhibition of TG2 in WT animals. In addition, the analysis of human liver samples from NAFLD patients validated the enzyme's involvement in the liver fat disease pathogenesis. Our findings strongly suggest that TG2 activation may offer protection in the context of NAFLD, thus representing a novel therapeutic target for tackling the NAFLD progression.

AB - Non-alcoholic fatty liver disease (NAFLD) is one of the most important liver diseases worldwide. Currently, no effective treatment is available, and NAFLD pathogenesis is incompletely understood. Transglutaminase type 2 (TG2) is a ubiquitous enzyme whose dysregulation is implicated in the pathogenesis of various human diseases. Here we examined the impact of TG2 on NAFLD progression using the high-fat-diet-induced model in both wild-type and TG2-deficient mice. Animals were fed with a standard chow diet or a high-fat diet (42% of the energy from fat) for 16 weeks. Results demonstrated that the absence of a functional enzyme, which causes the impairment of autophagy/mitophagy, leads to worsening of disease progression. Data were confirmed by pharmacological inhibition of TG2 in WT animals. In addition, the analysis of human liver samples from NAFLD patients validated the enzyme's involvement in the liver fat disease pathogenesis. Our findings strongly suggest that TG2 activation may offer protection in the context of NAFLD, thus representing a novel therapeutic target for tackling the NAFLD progression.

UR - http://www.scopus.com/inward/record.url?scp=85042199425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042199425&partnerID=8YFLogxK

U2 - 10.1038/s41419-018-0292-8

DO - 10.1038/s41419-018-0292-8

M3 - Article

AN - SCOPUS:85042199425

VL - 9

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 3

M1 - 257

ER -